Related Experiment Video
Updated: May 14, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Doxofylline and theophylline: a comparative clinical study
Md Faiz Akram1, Mohammad Nasiruddin, Zuber Ahmad
1Assistant Professor, Department of Pharmacology , KMCT Medical College Kozhikode, Kerala, India.
Journal of Clinical and Diagnostic Research : JCDR
|February 2, 2013
Summary
Doxofylline does not offer significant advantages over theophylline for treating Chronic Obstructive Pulmonary Disease (COPD) regarding efficacy or safety. Both medications showed comparable results in spirometric variables, symptom scores, and adverse effects in clinical practice.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) poses a significant global health challenge.
- Theophylline has a long history of use in COPD management.
- Doxofylline, a theophylline derivative, is marketed with claims of an improved safety profile.
Purpose of the Study:
- To compare the efficacy and safety of theophylline and doxofylline.
- Evaluate both drugs at commonly prescribed doses in clinical practice.
Main Methods:
- A randomized, prospective, open-label study involving 154 COPD patients.
- Group I received theophylline 400 mg SR once daily; Group II received doxofylline 400 mg twice daily.
- Assessed spirometric variables, symptom scores, and adverse effects over 21 days.
Main Results:
- No statistically significant differences were observed between the groups in spirometric variables.
- Symptom scores showed no significant variation between the theophylline and doxofylline groups.
- Adverse effects were comparable, with no significant difference noted (p>0.05).
Conclusions:
- Doxofylline demonstrated no superior efficacy compared to theophylline in COPD patients.
- The safety profiles of both theophylline and doxofylline were found to be similar at the studied doses.
- Current clinical practice doses of doxofylline offer no clear advantage over theophylline for COPD treatment.
Related Concept Videos
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28IV Infusion to Oral Dosing: Conversion Methods
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...